Physician profile
Robert B Hames
NPI 1558331504
$1,159.47
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $203.84 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $181.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.12 | 2019 | |
| Astellas Pharma US INC | $89.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $71.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.43 | 2019 | |
| Sunovion Pharmaceuticals INC. | $53.47 | 2019 | |
| Abbott Laboratories | $39.31 | 2019 | |
| Novo Nordisk INC | $36.81 | 2019 | |
| Genentech USA, INC. | $31.98 | 2019 | |
| Glaxosmithkline, LLC. | $29.50 | 2019 | |
| Amgen INC. | $25.89 | 2019 | |
| Si-Bone, INC. | $23.94 | 2019 | |
| Ethicon US, LLC | $22.27 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.84 | 2019 | |
| Lilly USA, LLC | $15.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.47 | 2019 | |
| Merck Sharp & Dohme LLC | $13.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hames listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.